Park Avenue Securities LLC Sells 5,385 Shares of Stryker Corporation $SYK

Park Avenue Securities LLC reduced its holdings in Stryker Corporation (NYSE:SYK) by 30.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,198 shares of the medical technology company’s stock after selling 5,385 shares during the period. Park Avenue Securities LLC’s holdings in Stryker were worth $3,359,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SYK. Segment Wealth Management LLC lifted its position in shares of Stryker by 5.6% in the 3rd quarter. Segment Wealth Management LLC now owns 59,971 shares of the medical technology company’s stock worth $16,515,000 after acquiring an additional 3,198 shares during the period. Verdence Capital Advisors LLC lifted its holdings in shares of Stryker by 103.6% during the 3rd quarter. Verdence Capital Advisors LLC now owns 28,206 shares of the medical technology company’s stock worth $7,768,000 after acquiring an additional 14,355 shares during the period. Noesis Capital Mangement Corp lifted its stake in Stryker by 36.3% during the third quarter. Noesis Capital Mangement Corp now owns 104,945 shares of the medical technology company’s stock worth $28,901,000 after purchasing an additional 27,938 shares during the period. Apollon Wealth Management LLC boosted its stake in Stryker by 21.2% in the 3rd quarter. Apollon Wealth Management LLC now owns 11,156 shares of the medical technology company’s stock valued at $3,072,000 after buying an additional 1,950 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC boosted its stake in shares of Stryker by 2.5% in the 3rd quarter. Kingswood Wealth Advisors LLC now owns 2,285 shares of the medical technology company’s stock valued at $629,000 after purchasing an additional 56 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SYK shares. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Raymond James Financial reissued an “outperform” rating and set a $323.00 price objective on shares of Stryker in a report on Friday. Wells Fargo & Company lowered their price objective on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. Finally, Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Sixteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $355.84.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Buying and Selling

In related news, Director Ronda Stryker sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $291.56 on Friday. The business’s 50-day simple moving average is $292.83 and its 200 day simple moving average is $324.51. The stock has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.83% and a net margin of 13.78%. Stryker’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.19 earnings per share. As a group, research analysts anticipate that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.